Biopharma | April 16, 2026
Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Through the partnership, she plans to share her experience—from consultation through recovery—across her social media platforms
A major push to sharpen the future of cancer treatment is underway
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
